Résumé
Objective To investigate the role of lncRNA PTENP1 in regulating TGF-β-induced epithelial-mesenchymal transition (EMT) in esophageal squamous cell carcinoma (ESCC). Methods Eca109 and TE-1 cells were treated with TGF-β1, and the expression of PTENP1 was detected by qRT-PCR before and after treatment. PTENP1-overexpressing stably transfected cell lines were constructed in Eca109 and TE-1 cells. The effects of overexpression of PTENP1 on TGF-β1-induced migration, proliferation and EMT-related proteins expression in Eca109 and TE-1 cells were detected by Transwell assay, CCK-8 test and Western blot, respectively. Results The expression of PTENP1 was significantly decreased in Eca109 and TE-1 cells treated with TGF-β1 (P < 0.05). Overexpression of PTENP1 significantly prevented cell migration, decreased the cell vitality, upregulated the E-cadherin expression, and downregulated the expression of N-cadherin and vimentin in Eca109 and TE-1 cells (P < 0.05). Furthermore, PTENP1 overexpression attenuated TGF-β-induced migration of Eca109 and TE-1 cells. PTENP1 overexpression partially reversed TGF-β-induced EMT (P < 0.05). Conclusion PTENP1 plays an important role in TGF-β-induced EMT in ESCC cells.
Résumé
Objective To investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer.Methods Clinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed.All patients were assigned into the radiochemotherapy (n=89)and chemotherapy groups (n=44).The survival analysis was performed by Kaplan-Meier method.The multivariate prognostic analysis was conducted by Cox's regression model.Results The 1-,2-and 3-year overall survival rates of the entire cohort were 53.5％,20.4％ and13.6％ respectively.Cox's regression analysis showed that gender,ECOG score,number of distant metastases,and whether the primary lesions received radiotherapy were the independent prognostic factors (all P＜0.05).The 1-,2-and 3-year survival rates in the radiochemotherapy group were 61％,29％ and19％,and 40％,4％,0％ in the chemotherapy group,respectively.In the radiochemotherapy group,the progression-free survival (PFS) and local progression-free survival (LPFS) were 8 months and 12.6 months,significantly longer compared with 4.7 months and 5.3 months in the chemotherapy group (both P＜0.05).The OS of patients receiving dose＞50Gy and ≤50Gy was 14.3 months and 8.2 months (P＜0.05),8.6 months and 2.8 months for the PFS (P＜0.05),and 15.2 months and 4.7 months for the LRFS (P＜0.05),respectively.The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P＜0.05).Conclusion Radiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer.
Résumé
Objective@#To investigate the clinical significance of radiotherapy for stage Ⅳ esophageal cancer.@*Methods@#Clinical data of 133 stage Ⅳ esophageal cancer patients admitted to our hospital from 2012 to 2018 were retrospectively analyzed. All patients were assigned into the radiochemotherapy (n=89) and chemotherapy groups (n=44). The survival analysis was performed by Kaplan-Meier method. The multivariate prognostic analysis was conducted by Cox’s regression model.@*Results@#The 1-, 2-and 3-year overall survival rates of the entire cohort were 53.5%, 20.4% and13.6% respectively. Cox’s regression analysis showed that gender, ECOG score, number of distant metastases, and whether the primary lesions received radiotherapy were the independent prognostic factors (all P<0.05). The 1-, 2-and 3-year survival rates in the radiochemotherapy group were 61%, 29% and19%, and 40%, 4%, 0% in the chemotherapy group, respectively. In the radiochemotherapy group, the progression-free survival (PFS) and local progression-free survival (LPFS) were 8 months and 12.6 months, significantly longer compared with 4.7 months and 5.3 months in the chemotherapy group (both P<0.05). The OS of patients receiving dose> 50Gy and ≤50Gy was 14.3 months and 8.2 months (P<0.05), 8.6 months and 2.8 months for the PFS (P<0.05), and 15.2 months and 4.7 months for the LRFS (P<0.05), respectively. The number of distant metastases and the clinical efficacy for primary lesions were the independent prognostic factors in the radiochemotherapy group (both P<0.05).@*Conclusion@#Radiotherapy can improve the clinical prognosis of patients with stage Ⅳ esophageal cancer.